Glyburide and glipizide in treatment of diabetic patients with secondary failures to tolazamide or chlorpropamide.
We evaluated therapeutic usefulness of the second-generation sulfonylurea agents glyburide and glipizide in non-insulin-dependent diabetic patients who were secondary failures on chlorpropamide or tolazamide. Twenty patients were treated with glyburide, and 10 of them were subsequently treated with glipizide. Fasting and postprandial serum glucose, insulin, C-peptide, glycosylated hemoglobin, urinary C-peptide, and glucose levels all failed to show significant improvement. We concluded that both glyburide and glipizide proved ineffective in the treatment of secondary failures to first-generation sulfonylureas.
D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood / Q000652:urine; D002747:Chlorpropamide / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D004435:Eating; D005215:Fasting; D005913:Glipizide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*; D014042:Tolazamide / Q000627:therapeutic use*
D001786:Blood Glucose; D002096:C-Peptide; D002747:Chlorpropamide; D005913:Glipizide; D005905:Glyburide; D006442:Glycated Hemoglobin; D007328:Insulin; D013453:Sulfonylurea Compounds; D014042:Tolazamide